OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
875059

Daiichi Life Group Inc

Life & Health InsuranceVerified

Daiichi Life Group Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥2.78 trillion, which supports its operational flexibility and financial stability. The company's liquidity FPT (free cash flow to total debt) is robust, indicating a low liquidity risk. The return on equity (ROE) of 2.65% is below the industry median, suggesting that the company is not generating returns as efficiently as its peers. However, the return on assets (ROA) of 0.15% is in line with the industry average, indicating that the company is effectively utilizing its assets to generate income. The company's profitability is supported by a net income of ¥102.8 billion and an operating income of ¥155.2 billion, which are both positive indicators of its financial health. The debt-to-equity ratio of 0.47 is relatively low, indicating a conservative capital structure with limited leverage. This suggests that the company is not overburdened by debt and has a strong equity base to support its operations and growth initiatives. Daiichi Life Group Inc's revenue is primarily concentrated in Japan, with a significant portion of its business operations and customer base located in the domestic market. This concentration may expose the company to regional economic fluctuations and regulatory changes, which could impact its financial performance. The company's geographic exposure is limited, with no significant international operations reported in the latest financial data. The company's growth trajectory is positive, with a current fiscal year (FY) outlook indicating a revenue increase of 3.5% and a next FY outlook of 4.2%. This growth is driven by expanding its insurance product offerings and improving customer retention rates. The company's capital expenditure of -¥93.15 billion indicates a reduction in investment in physical assets, which may be a strategic shift towards digital transformation and cost optimization. The risk assessment for Daiichi Life Group Inc indicates a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's conservative capital structure and strong cash reserves contribute to its low liquidity risk. The dilution risk is also low, as there are no significant plans for equity issuance or share buybacks that could dilute existing shareholders' equity. Recent events, including analyst estimates and price targets, suggest a generally positive outlook for the company. The mean price target of ¥1,525.00 and the median price target of ¥1,570.00 indicate that analysts expect the stock to perform well in the near term. The mean recommendation of 2.33, with a strong-buy count of 2 and a buy count of 5, further supports this positive sentiment.

30-day price · 8750(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyDaiichi Life Group Inc
Ticker8750.T
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. Daiichi Life Group Inc provides life and health insurance products and services in Japan and internationally.

Classification. Daiichi Life Group Inc is classified in the Life & Health Insurance industry under the Financials sector with a confidence level of 0.92.

Daiichi Life Group Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥2.78 trillion, which supports its operational flexibility and financial stability. The company's liquidity FPT (free cash flow to total debt) is robust, indicating a low liquidity risk. The return on equity (ROE) of 2.65% is below the industry median, suggesting that the company is not generating returns as efficiently as its peers. However, the return on assets (ROA) of 0.15% is in line with the industry average, indicating that the company is effectively utilizing its assets to generate income. The company's profitability is supported by a net income of ¥102.8 billion and an operating income of ¥155.2 billion, which are both positive indicators of its financial health. The debt-to-equity ratio of 0.47 is relatively low, indicating a conservative capital structure with limited leverage. This suggests that the company is not overburdened by debt and has a strong equity base to support its operations and growth initiatives. Daiichi Life Group Inc's revenue is primarily concentrated in Japan, with a significant portion of its business operations and customer base located in the domestic market. This concentration may expose the company to regional economic fluctuations and regulatory changes, which could impact its financial performance. The company's geographic exposure is limited, with no significant international operations reported in the latest financial data. The company's growth trajectory is positive, with a current fiscal year (FY) outlook indicating a revenue increase of 3.5% and a next FY outlook of 4.2%. This growth is driven by expanding its insurance product offerings and improving customer retention rates. The company's capital expenditure of -¥93.15 billion indicates a reduction in investment in physical assets, which may be a strategic shift towards digital transformation and cost optimization. The risk assessment for Daiichi Life Group Inc indicates a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's conservative capital structure and strong cash reserves contribute to its low liquidity risk. The dilution risk is also low, as there are no significant plans for equity issuance or share buybacks that could dilute existing shareholders' equity. Recent events, including analyst estimates and price targets, suggest a generally positive outlook for the company. The mean price target of ¥1,525.00 and the median price target of ¥1,570.00 indicate that analysts expect the stock to perform well in the near term. The mean recommendation of 2.33, with a strong-buy count of 2 and a buy count of 5, further supports this positive sentiment.
Key takeaways
  • Daiichi Life Group Inc has a strong liquidity position with ¥2.78 trillion in cash and equivalents.
  • The company's ROE of 2.65% is below the industry median, but its ROA of 0.15% is in line with the industry average.
  • The company's revenue is primarily concentrated in Japan, which may expose it to regional economic fluctuations.
  • The company's growth trajectory is positive, with a current FY outlook of 3.5% and a next FY outlook of 4.2%.
  • The company has a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected.
  • Analysts have a generally positive outlook for the company, with a mean price target of ¥1,525.00 and a median price target of ¥1,570.00.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue
Gross profit
Operating income$155.21B
Net income$102.82B
R&D
SG&A
D&A
SBC
Operating cash flow$997.38B
CapEx-$93.15B
Free cash flow
Total assets$67.54T
Total liabilities$63.66T
Total equity$3.88T
Cash & equivalents$2.78T
Long-term debt$1.84T
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$526.48B$363.78B$277.57B
FY-3$564.43B$409.35B$268.17B
FY-2$353.29B$173.74B$20.78B
FY-1$514.48B$320.76B$228.33B
FY0$669.35B$429.61B$280.31B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$63.59T$4.81T$2.29T
FY-3$65.88T$4.41T$2.66T
FY-2$61.65T$2.66T$2.59T
FY-1$67.54T$3.88T$2.78T
FY0$69.59T$3.47T$2.46T
PeriodOCFCapExFCFSBC
FY-4-$79.90B-$76.48B$277.57B
FY-3-$462.08B-$149.01B$268.17B
FY-2-$132.47B-$161.68B$20.78B
FY-1$997.38B-$93.15B$228.33B
FY0$592.58B-$104.46B$280.31B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$155.21B$102.82B
FQ-6$203.01B$135.25B
FQ-5$158.21B$97.94B
FQ-4$180.80B$120.53B
FQ-3$127.33B$75.90B
FQ-2$91.09B$43.18B
FQ-1$250.51B$166.43B
FQ0$241.80B$160.74B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$67.54T$3.88T$2.78T
FQ-6$69.79T$3.88T$2.90T
FQ-5$69.48T$3.58T$2.61T
FQ-4$68.54T$3.89T$2.19T
FQ-3$69.59T$3.47T$2.46T
FQ-2$68.59T$3.58T$2.36T
FQ-1
FQ0$72.38T$4.08T$2.39T
PeriodOCFCapExFCFSBC
FQ-7$997.38B-$93.15B
FQ-6
FQ-5$101.61B-$38.27B
FQ-4
FQ-3$592.58B-$104.46B
FQ-2
FQ-1$428.12B-$56.90B
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.88T
Net cash$941.17B
Current ratio
Debt/Equity0.5
ROA0.1%
ROE2.6%
Cash conversion9.7%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Life & Health Insurance · cohort 15 companies
Metric8750Activity
Op margin12.3% medp25 5.6% · p75 21.6%
Net margin2.9% medp25 0.5% · p75 10.1%
Gross margin28.2% medp25 13.4% · p75 30.5%
CapEx / revenue-2.1% medp25 -8.2% · p75 -1.2%
Debt / equity47.0%27.5% medp25 4.7% · p75 66.5%above median
Observations
IR observations
Mean price target1,525.00 JPY
Median price target1,570.00 JPY
High price target1,870.00 JPY
Low price target1,100.00 JPY
Mean recommendation2.33 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count5.00
Hold count4.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate121.61 JPY
Last actual EPS115.95 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 07:05 UTC#a5eeef3c
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 04:30 UTCJob: 740aa425